| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0755-4982(04)98729-5 |
| P698 | PubMed publication ID | 15257230 |
| P2093 | author name string | Joël Ménard | |
| P2860 | cites work | Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 | Q22010575 |
| Risk factor thresholds: their existence under scrutiny | Q24527206 | ||
| Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis | Q24679573 | ||
| Atherosclerosis — An Inflammatory Disease | Q26776972 | ||
| Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies | Q28036762 | ||
| Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group | Q28141498 | ||
| Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators | Q28144781 | ||
| Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack | Q28190600 | ||
| Role of prostacyclin in the cardiovascular response to thromboxane A2 | Q28192832 | ||
| Structure-based design of aliskiren, a novel orally effective renin inhibitor | Q28202603 | ||
| The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE> | Q28204197 | ||
| Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass | Q28360314 | ||
| Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) | Q29618529 | ||
| Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation | Q30310896 | ||
| Prevalence, treatment, and control of hypertension in the French population: data from a survey on high blood pressure in general practice, 1994. | Q32055903 | ||
| Molecular mechanisms of human hypertension | Q32138445 | ||
| Seven lessons from two candidate genes in human essential hypertension: angiotensinogen and epithelial sodium channel | Q33663001 | ||
| Pressure-independent contribution of sodium to large artery structure and function in hypertension | Q33895496 | ||
| Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients | Q33947313 | ||
| Differential Control of Systolic and Diastolic Blood Pressure | Q57740570 | ||
| Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist | Q59065030 | ||
| LOCALISATION OF 11β-HYDROXYSTEROID DEHYDROGENASE—TISSUE SPECIFIC PROTECTOR OF THE MINERALOCORTICOID RECEPTOR | Q60628255 | ||
| Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor | Q67494059 | ||
| Physiological and immunopathological consequences of active immunization of spontaneously hypertensive and normotensive rats against murine renin | Q68512696 | ||
| Hypertension of renal origin: evidence for two different mechanisms | Q68636224 | ||
| Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles | Q68669670 | ||
| Antialdosterones: incidence and prevention of sexual side effects | Q69940156 | ||
| Why do we need some large, simple randomized trials? | Q70760033 | ||
| Vegetable, fruit, and cereal fiber intake and risk of coronary heart disease among men | Q71073197 | ||
| Intake of dietary fiber and risk of coronary heart disease in a cohort of Finnish men. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study | Q71828306 | ||
| Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart | Q71844423 | ||
| Tissue angiotensin system in cardiovascular medicine. A paradigm shift? | Q72708449 | ||
| Myocardial fibrosis in the rat with mineralocorticoid excess. Prevention of scarring by amiloride | Q72861447 | ||
| Measuring blood pressure accurately: new and persistent challenges | Q73028753 | ||
| The physiological response to cardiovascular 'orphan' G protein-coupled receptor agonists | Q73143605 | ||
| The absolute risk as a guide to influence the treatment decision-making process in mild hypertension | Q74192217 | ||
| Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation | Q74230761 | ||
| ALDOSTERONE SECRETION AND VARIOUS FORMS OF HYPERTENSIVE VASCULAR DISEASE | Q76499012 | ||
| THE ROLE OF BLOOD-PRESSURE CONTROL IN PREVENTING COMPLICATIONS OF HYPERTENSION | Q76644397 | ||
| Dietary sodium and target organ damage in essential hypertension | Q77898044 | ||
| Genetic variation in aldosterone synthase predicts plasma glucose levels | Q33949240 | ||
| Pulse pressure, arterial stiffness, and cardiovascular risk | Q34119064 | ||
| Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis | Q34198795 | ||
| Anti-inflammatory mechanisms in the vascular wall. | Q34249006 | ||
| Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials | Q34276433 | ||
| Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? | Q34395664 | ||
| Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial | Q34502430 | ||
| Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol | Q34522261 | ||
| Active immunization against renin in normotensive marmoset | Q34633508 | ||
| Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system. | Q34781131 | ||
| Sgk: an old enzyme revisited | Q34816111 | ||
| Design of Specific Inhibitors of Angiotensin-Converting Enzyme: New Class of Orally Active Antihypertensive Agents | Q34936463 | ||
| Is the relation of systolic blood pressure to risk of cardiovascular disease continuous and graded, or are there critical values? | Q35219518 | ||
| The pharmaceutical industry versus Medicaid--limits on state initiatives to control prescription-drug costs | Q35648505 | ||
| Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). | Q36456306 | ||
| Why do the kidneys release renin in patients with congestive heart failure? A nephrocentric view of converting-enzyme inhibition | Q37936796 | ||
| Variation at the aldosterone synthase (CYP11B2) locus contributes to hypertension in subjects with a raised aldosterone-to-renin ratio. | Q38363260 | ||
| Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group | Q39589083 | ||
| Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials | Q39607981 | ||
| Factors associated with conversion to laparotomy in patients undergoing laparoscopic appendectomy | Q40586796 | ||
| Expression of 11 beta-OHSD along the nephron of mammals and humans | Q40756222 | ||
| Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril | Q41486237 | ||
| Future drug research-drugs of the future | Q41542477 | ||
| Additive Effects of Combined Angiotensin-Converting Enzyme Inhibition and Angiotensin II Antagonism on Blood Pressure and Renin Release in Sodium-Depleted Normotensives | Q41679821 | ||
| United States wins more time to lobby against WHO diet plan | Q43138150 | ||
| Effects of combined administration of ACE inhibitor and angiotensin II receptor antagonist are prevented by a high NaCl intake | Q43777451 | ||
| Cardiovascular protection and blood pressure reduction: a meta-analysis | Q43782892 | ||
| Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing | Q43874204 | ||
| Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol | Q43950414 | ||
| Effects of fruit and vegetable consumption on plasma antioxidant concentrations and blood pressure: a randomised controlled trial | Q44036535 | ||
| Results of the Diet, Exercise, and Weight Loss Intervention Trial (DEW-IT). | Q44201657 | ||
| False claims of blood pressure-independent protection by blockade of the renin angiotensin aldosterone system? | Q44306663 | ||
| Safety and statin therapy: reconsidering the risks and benefits | Q44363458 | ||
| Amiloride reduces stroke and renalinjury in stroke-prone hypertensive rats | Q44387223 | ||
| Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial | Q44412919 | ||
| Results of the pilot study for the Hypertension in the Very Elderly Trial | Q44679389 | ||
| Erectile dysfunction in essential arterial hypertension and effects of sildenafil: results of a Spanish national study | Q44748488 | ||
| Molecular basis of human hypertension: role of angiotensinogen | Q45118696 | ||
| Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats | Q47298474 | ||
| Physiological genomics of human arteries: quantitative relationship between gene expression and arterial stiffness | Q47581942 | ||
| The potential impact of nonpharmacologic population-wide blood pressure reduction on coronary heart disease events: pronounced benefits in African-Americans and hypertensives | Q47608455 | ||
| Benefit of a favorable cardiovascular risk-factor profile in middle age with respect to Medicare costs. | Q50634818 | ||
| Risk assessment and treatment benefit in intensively treated hypertensive patients of the hypertension Optimal Treatment (HOT) study. | Q52064617 | ||
| Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure | Q57259661 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | French | Q150 |
| P304 | page(s) | 721-732 | |
| P577 | publication date | 2004-06-01 | |
| P1433 | published in | Presse médicale | Q127260618 |
| P1476 | title | [What progress can be expected in the management of hypertension? Forecast from 1974 to 2034] | |
| P478 | volume | 33 |
| Q58770012 | : A New Way to Assess the Quality of Healthcare by Examining Causes of Premature Death for Which Highly Efficacious Medical Interventions Are Available | cites work | P2860 |
Search more.